Repligen Corp
Repligen Corp price
About Repligen Corp
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
- Stock ticker
- RGEN
- Company
- Repligen Corporation
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- Apr 29, 1986
- Listed exchange
- NASDAQ
Financials
Summary: RGEN reported Revenue of 204.13M (+11.93%), beating expectations; EPS of 0.54 (+45.95%), beating expectations.
Repligen Corp conversion tables
 |  |
|---|---|
| 0.5 RGEN | 86.92 USD |
| 1 RGEN | 173.84 USD |
| 5 RGEN | 869.2 USD |
| 10 RGEN | 1,738.4 USD |
| |
|---|---|
| 0.5 USD | 0.0028762 RGEN |
| 1 USD | 0.0057524 RGEN |
| 5 USD | 0.028762 RGEN |
| 10 USD | 0.057524 RGEN |
More to explore
FAQ
RGEN is trading at $173.84, -0.02% over the last 24 hours. Track live moves on the price chart at the top of this page.
The RGEN stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. RGEN is currently trading at $173.84, -0.02% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on RGEN price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. RGEN's P/E ratio is currently 238.19 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from RGEN; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against RGEN's historical range and other companies in the Healthcare sector.
Repligen Corporation's market cap is currently 9.81B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.